GlassScriptPhysician profile
Senan John Yasar
NPI 1891177127
$5,218.79
in general payments reported to CMS, 2019-2025
15 companies · $291 in 2025
The $291 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,851 · 2020: $1,044 · 2021: $212 · 2022: $303 · 2023: $148 · 2024: $370 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,094.25 | 2019-2021 | |
| Amgen INC. | $393.04 | 2019-2025 | Repatha |
| Medtronic Vascular, INC. | $261.74 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $187.05 | 2021-2023 | Andexxa |
| Heartflow, INC. | $171.83 | 2025 | |
| Biotronik INC. | $165.23 | 2022-2023 | Orsiro Mission, Recross, Pk Papyrus |
| E.R. Squibb & Sons, L.L.C. | $161.87 | 2022-2024 | Camzyos |
| Boston Scientific Corporation | $159.86 | 2019-2020 | |
| Novo Nordisk INC | $150.43 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $123.97 | 2024 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $97.29 | 2022-2025 | |
| Medtronic, INC. | $72.75 | 2021-2024 | Symplicity G3 |
| Edwards Lifesciences Corporation | $57.42 | 2019-2024 | |
| Ge Healthcare | $23.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Senan Yasar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.